SCHEMBL13623299

SCHEMBL13623299

COC(=O)Cn1c(=O)oc2c(CCc3cccc(NC(=O)OC(C)(C)C)c3)cc(Nc3nc(Cl)ncc3Cl)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL6 P41182 1/20 0.37
STK17B O94768 1/20 0.35
STK17A Q9UEE5 1/20 0.35
SYK P43405 1/20 0.35
MET P08581 1/20 0.34
BRD4 O60885 3/20 0.34
JAK3 P52333 2/20 0.33
AURKA O14965 1/20 0.33
RPS6KB1 P23443 1/20 0.33
BTK Q06187 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
P2RX7 Q99572 1/20 0.33
F2RL3 Q96RI0 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
AKT1 P31749 1/20 0.32
CBX7 O95931 1/20 0.32
RECQL P46063 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CDYL2 Q8N8U2 1/20 0.32
CDYL Q9Y232 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4365344 0.94 BCL6 (0.38) BCL6STK17BSTK17ASYKMET
SCHEMBL13623303 0.88 BCL6 (0.36) BCL6STK17BSTK17ASYKMET
SCHEMBL4485009 0.87 BCL6 (0.36) BCL6STK17BSTK17ASYKMET
SCHEMBL13670011 0.87 BCL6 (0.37) BCL6
SCHEMBL13623300 0.82 SMN1; SMN2 (0.38) BRD4AURKARPS6KB1TLR7F2RL3
SCHEMBL4356005 0.79 BCL6 (0.35) BCL6JAK3AURKABTK
SCHEMBL1027969 0.79 EGFR (0.43) STK17BSTK17ASYKMETJAK3
SCHEMBL13622745 0.79 SYK (0.43) BCL6STK17BSTK17ASYKMET
SCHEMBL1025626 0.78 SYK (0.42) BCL6STK17BSTK17ASYKMET
SCHEMBL1024064 0.77 STK17B (0.43) STK17BSTK17ASYKMETBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK BCL6 392/4885STK17B 139/4885STK17A 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.